Who are Lycia Therapeutics's investors?

Lycia Therapeutics's investors include REDMILE, Versant Ventures, HBM Healthcare Investments, HBM Partners, BAM Elevate, Franklin Templeton, Invus, Janus Henderson Investors and 4 more.

How much funding has Lycia Therapeutics raised?

Lycia Therapeutics has disclosed $277M raised across 4 rounds.

Where is Lycia Therapeutics headquartered?

Lycia Therapeutics is headquartered in South San Francisco, US.

Lycia Therapeutics

South San Francisco, US · Founded 2019 · Delaware corporation · 36 employees on LinkedIn · 13 known investors

Find your way into Lycia Therapeutics

288 people in our graph share verified history with the Lycia Therapeutics team — schools, employers, funds. One of them is your warm intro.

Kara Holinskiunlockedknows Amy Bachrodt · together at Myovant Sciences (overlapped)

×3knows the team · via Maze Therapeutics

×7knows the team · via Ey

knows the team · via Myovant Sciences

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.

Biotech Healthtech

Founders & leadership

Aetna Wun TrombleyChief Executive Officer

Amy Bachrodt Chief Financial OfficerAmy Bachrodt is Chief Financial Officer at Lycia Therapeutics, a biotechnology company developing targeted protein degradation therapeutics. She brings 15 years of financial and operational leadership experience across drug development, manufacturing, and commercialization at both public and private biotech companies.

Chin LeeChief Medical Officer

Steve StabenChief Scientific Officer

Sofia TouamiChief Business Officer

Karen FlickGeneral Counsel

Jeremy S. Caldwell Named on SEC filingVenture Partner at Versant Ventures

Carolyn Bertozzi Lycia founder and Professor of Chemistry, Stanford UniversityShe joined the Stanford faculty in 2015 after nearly two decades at the University of California, Berkeley, where she held a joint appointment in chemistry and molecular and cell biology. She earned her PhD at Berkeley and completed postdoctoral training at the University of California, San Francisco.

Aetna Wun Trombley, Ph.D.President and CEO

Board

Clare Ozawa Board directorManaging Director at Versant Ventures

Thomas Woiwode Board directorManaging Director at Versant Ventures

Tim AndersonBoard director

Investors · 13

REDMILE✓ confirmed by Lycia TherapeuticsSan Francisco

How we know: the company's own site · Not right? Tell us

Versant Ventures✓ confirmed by Lycia TherapeuticsSan Francisco · $250K – $5Mvia Clare Ozawa · board

How we know: the company's own site · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

HBM Healthcare Investmentslisted by HBM Healthcare InvestmentsZug

How we know: HBM Healthcare Investments's portfolio page · offering press articles · allsci.com · Not right? Tell us

HBM Partnerslisted by HBM PartnersZug · $5M – $50M

How we know: HBM Partners's portfolio page · Not right? Tell us

BAM ElevatereportedChicago

How we know: offering press articles · allsci.com · funding news · Not right? Tell us

Franklin TempletonreportedSan Mateo

How we know: offering press articles · allsci.com · Not right? Tell us

InvusreportedNew York

How we know: allsci.com · Not right? Tell us

Janus Henderson InvestorsreportedNew York

How we know: offering press articles · allsci.com · funding news · Not right? Tell us

OrbiMedreportedNew York · $1M – $75M

How we know: offering press articles · allsci.com · Not right? Tell us

RTW Investments L.P.reportedNew York

How we know: a partner's Signal profile · offering press articles · allsci.com · Not right? Tell us

Venrock Healthcare Capital PartnersreportedNew York

How we know: offering press articles · allsci.com · Not right? Tell us

Versant Venture CapitalinferredSan Francisco

How we know: board seat on SEC Form D · Not right? Tell us

Also in the syndicate · 1

Eli Lilly and Company

Reported raises · per SEC filings

Form D private placements

$277M disclosed across 4 rounds · 2020–2026

▶$75MraisedJun 2026 · 16 investors · Biotechnology

Rule 506(b)

Lycia Therapeutics Raises $75M in Series D Fundingfinsmes.com · Jun 2026

Officers, directors & promoters on the filing

Tim AndersonDirector
William RieflinDirector
Clare OzawaDirector
Aetna Wun TrombleyExecutive Officer, Director
Laurent FischerDirector
Ming FangDirector
Amy BachrodtExecutive Officer

Offering amount: $75M
Amount sold: $75M
First sale: Jun 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$106.6MraisedMay 2024 · 16 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ming FangDirector
Laurent FischerDirector
Tim AndersonDirector
Andrew GottesdienerDirector
William RieflinDirector
Clare OzawaDirector
Aetna Wun TrombleyExecutive Officer, Director

Offering amount: $106.6M
Amount sold: $106.6M
First sale: Apr 2024
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$70.1MraisedSep 2021 · 11 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laurent FischerDirector
William RieflinDirector
Clare OzawaDirector
Thomas WoiwodeDirector
Tim AndersonDirector
Aetna Wun TrombleyExecutive Officer, Director

Offering amount: $70.1M
Amount sold: $70.1M
First sale: Sep 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25.4MraisedMar 2020 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Clare OzawaDirector
Thomas WoiwodeDirector
Laurent FischerDirector
Jeremy S. CaldwellExecutive Officer, Director

Offering amount: $50.4M
Amount sold: $25.4M
Minimum investment: $1
First sale: Mar 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Eli Lilly21 shared keywordsEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Intellia Therapeutics18 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

Kite Pharma17 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

Coya Therapeutics16 shared keywordsCoya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell (Treg) therapeutic modalities to treat neurodegenerative, autoimmune, and metabolic diseases. Its programs include the ALSTARS clinical trial in ALS.

Altay Therapeutics15 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

Companies competing with Lycia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Lycia Therapeutics Raises $75M in Series D Fundingfinsmes.com · Jun 2026

Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counsel - BioSpacebiospace.com · Jun 2026

Lycia Therapeutics Raises $75 Million in Oversubscribed Financing and Strengthens Leadership Team with Appointment of Chief Financial Officer and General Counselglobenewswire.com · Jun 2026

Frequently asked questions

What does Lycia Therapeutics do?: Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.
Who are Lycia Therapeutics's investors?: Lycia Therapeutics's investors include REDMILE, Versant Ventures, HBM Healthcare Investments, HBM Partners, BAM Elevate, Franklin Templeton, Invus, Janus Henderson Investors and 4 more.
How much funding has Lycia Therapeutics raised?: Lycia Therapeutics has disclosed $277M raised across 4 rounds.
Where is Lycia Therapeutics headquartered?: Lycia Therapeutics is headquartered in South San Francisco, US.